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Introduction
Various clinical tools exist that categorize health-care
data into homogenous cohorts. The tools contribute to
the understanding of health-care experiences. The tools
described below are used in understanding the Discov-
ery Health population.
At a patient level, the John Hopkins Adjusted Clinical
Groups (ACG) case-mix system identifies common com-
binations of disease that impact on each other to
increase an individual’s risk. The tool is thus robust not
only in categorizing patient illness, but also in analyzing
health-care utilization and cost.
At an episode of care level, the Discovery Episode
grouper (DEG) uses ICD-10 coded data to define epi-
sodes. These episodes provide a means for assessing
health-care quality and cost.
At the hospital level the Diagnosis Related Group
(DRG), a patient classification system, provides an
understanding of the costs incurred by measuring the
case-mix index of a hospital.
Using the ACG, DEG and DRG, Discovery Health data
can be segregated into various resource bands. High-
cost members can be identified, and the costs incurred
by different providers assessed.
Studies done in various regions in the United States
have shown that Medicare spending varies in different
areas across the country. Stephan Zuckerman explains
that “geographic differences in Medicare spending are
not necessarily evidence of inefficiency in health care,”
and that “29% of the differences can be attributed to
health, but 33% remains unexplained”.
Using region as a starting point, the aim of this pro-
ject is to understand how much of the differences in
health-care cost identified can be explained using the
clinical tools. This explainable portion is due to the dif-
ference in population demographics and disease burden
within different regions. Possible explanatory factors for
the residual differences will be explored, with regional
differences forming the starting point of the study.
Methods
Assess and understand the disease burden in various
regions by categorizing members into different resource
utilization bands (RUBs) using the ACGs.
Identify diseases that exist within the RUBs using the
DRGs for hospital cases, DEG for separate episodes, and
the Discovery Health Label Matrix for a combined epi-
sode view.
Adjust for differences in disease burden and episodes
of care in the different provinces, define other factors
contributing to differences in health-care costs, leaving
an unexplained inefficiency/efficiency cost per province
to be explained.
Results
RUB distributions were as follows: Free State had the
highest number of RUB 5 members (2.3%), followed by
Gauteng (1.5%), Mpumalanga and North West (1.4%),
Limpopo, Northern Cape and Eastern Cape (1.3%),
KwaZulu Natal (1.2%) and Western Cape (1.1%).
The distribution of RUB 4 members in the country
was 7.5% in the Free State, 7.3% in Gauteng, 6.2% in
Mpumalanga, 6% in Eastern Cape, 5.9% in North West
and Northern Cape, 5.8% in KwaZulu Natal and Lim-
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The majority of RUB 3 members are found in
Gauteng (42.6%), with Eastern Cape (38.8%), Free State
(38.6%), Mpumalanga (37.0%), KwaZulu Natal (36.2%),
Western Cape (35.8%), North West (34.4%), Northern
Cape (34.1%) and Limpopo (33.7%) following.
RUB 2 users were distributed in Mpumalanga (22.3%),
North West (22.2%), Gauteng (21.4%), Limpopo (21.2%),
Eastern Cape (21.1%), KwaZulu Natal (21.0%), Western
Cape (20.8%,), Northern Cape (20.1%) and Free State
(19.9%).
Members who were considered to be healthy users
and categorized into RUB 1 were 17.0% in the Western
Cape, 16.8% in the Eastern Cape and KwaZulu Natal,
16.5 % in the Northern Cape, 16.2% in Limpopo, 15.9%
in Mpumalanga, 15.5% in North West, 15.4% in Gau-
teng and 14.5% in the Free State. The highest numbers
of non-users were found in Northern Cape (22.2%).
Limpopo had 21.8% and North West had 21.0% of non-
users. In Western Cape and KwaZulu Natal, 19.8% and
19.0% of non-users were found, respectively. Just over
17% of non-users were in Mpumalanga (17.3%) and Free
State (17.2%), and the lowest number of non-users was
distributed with Gauteng (11.8%).
After adjusting for the different RUB distribution of
patients in different provinces, costs for both Gauteng
and Free State were higher than that predicted by 4%
and 2%, respectively. The costs for Gauteng and Free
State were also above the average cost due to the high
proportion of RUB 4 and RUB 5 members. Further
investigation is required to understand this residual.
Conclusions
There are distinct geographical differences within South
Africa, with higher costs incurred in higher-cost areas.
Further analyses are underway to obtain a greater
understanding of other factors that may be contributing
to the unexplained differences in health-care costs
experienced by different provinces.
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